

Northern Health Authority Annual Antibigram 2025*

Greater than or equal to 80% susceptibility = GOOD CHOICE							Less than 80% susceptibility = POOR CHOICE										
Northern Health Authority Gram Negative Organisms % Susceptible	# of isolates	Amoxicillin/ Clavulanate		Ampicillin	Piperacillin/ Tazobactam	Cefazolin	Cefuroxime	Cefixime	Cefotaxime or Ceftriaxone	Ceftazidime	Meropenem	Gentamicin	Tobramycin	TMP/SMX	Ciprofloxacin	Moxifloxacin	Nitrofurantoin ^u
<i>Escherichia coli</i>	4362	88	62	98	87	–	89	92	–	100	93	94	83	74	–	97	
<i>Citrobacter freundii</i>	79	R	R	R	R	R	R	R	–	100	92	96	89	87	–	91	
<i>Enterobacter cloacae complex^a</i>	279	R	R	–	R	–	–	–	–	99	94	94	88	88	–	34	
<i>Klebsiella aerogenes^b</i>	65	R	R	–	R	–	–	–	–	100	92	95	97	91	–	9	
<i>Klebsiella oxytoca</i>	162	88	R	91	59	–	92	88	94	99	94	95	94	95	–	96	
<i>Klebsiella pneumoniae</i>	541	96	R	97	92	–	93	94	94	100	97	97	93	88	–	39	
<i>Morganella morganii</i>	46	R	R	–	R	R	–	–	–	100	85	90	76	74	–	–	
<i>Proteus mirabilis</i>	240	98	86	100	91	–	97	99	–	100	93	90	88	93	–	–	
<i>Serratia marcescens</i>	54	R	R	–	R	R	–	–	–	93	93	76	98	91	–	R	
<i>Pseudomonas aeruginosa</i>	324	R	R	89	–	–	–	R	93	90	–	99	R	87	–	–	
<i>Stenotrophomonas maltophilia</i>	25	R	R	R	–	–	–	R	R	R	–	–	92	–	–	–	
<i>Haemophilus influenzae</i>	79	82	81	–	–	95	–	100	–	–	–	–	67	–	100	–	

Notes Percent susceptible for each organism/antimicrobial combination was generated by including the first isolate of that organism encountered on a given patient.
Organisms with less than 30 isolates have decreased statistical validity.

Legend – Drug not tested or indicated
^u Urinary tract infections only
R Intrinsic resistance
^a Enterobacter cloacae complex includes Enterobacter asburiae, E. cloacae and E. hormaechei
^b Previously known as Enterobacter aerogenes



10-201-6002 (FF09650–IND–Rev.–05/25)

Northern Health Authority Annual Antibigram 2025*

Greater than or equal to 80% susceptibility = GOOD CHOICE							Less than 80% susceptibility = POOR CHOICE									
Northern Health Authority Gram Negative Organisms % Susceptible	# of Isolates															
		Amoxicillin/ Clavulanate	Ampicillin	Piperacillin/ Tazobactam	Cefazolin	Cefuroxime	Cefixime	Cefotaxime or Ceftriaxone	Ceftazidime	Meropenem	Gentamicin	Tobramycin	TMP/SMX	Ciprofloxacin	Moxifloxacin	Nitrofurantoin ^u
<i>Escherichia coli</i>	4362	88	62	98	87	–	89	92	–	100	93	94	83	74	–	97
<i>Citrobacter freundii</i>	79	R	R	R	R	R	R	R	–	100	92	96	89	87	–	91
<i>Enterobacter cloacae complex</i> ^a	279	R	R	–	R	–	–	–	–	99	94	94	88	88	–	34
<i>Klebsiella aerogenes</i> ^b	65	R	R	–	R	–	–	–	–	100	92	95	97	91	–	9
<i>Klebsiella oxytoca</i>	162	88	R	91	59	–	92	88	94	99	94	95	94	95	–	96
<i>Klebsiella pneumoniae</i>	541	96	R	97	92	–	93	94	94	100	97	97	93	88	–	39
<i>Morganella morganii</i>	46	R	R	–	R	R	–	–	–	100	85	90	76	74	–	–
<i>Proteus mirabilis</i>	240	98	86	100	91	–	97	99	–	100	93	90	88	93	–	–
<i>Serratia marcescens</i>	54	R	R	–	R	R	–	–	–	93	93	76	98	91	–	R
<i>Pseudomonas aeruginosa</i>	324	R	R	89	–	–	–	R	93	90	–	99	R	87	–	–
<i>Stenotrophomonas maltophilia</i>	25	R	R	R	–	–	–	R	R	R	–	–	92	–	–	–
<i>Haemophilus influenzae</i>	79	82	81	–	–	95	–	100	–	–	–	–	67	–	100	–

Notes Percent susceptible for each organism/antimicrobial combination was generated by including the first isolate of that organism encountered on a given patient.
Organisms with less than 30 isolates have decreased statistical validity.

Legend – Drug not tested or indicated
^u Urinary tract infections only
R Intrinsic resistance
^a Enterobacter cloacae complex includes Enterobacter asburiae, E. cloacae and E. hormaechei
^b Previously known as Enterobacter aerogenes



10-201-6002 (FF09650–IND–Rev.–05/25)

Northern Health Authority Annual Antibigram 2025*

Greater than or equal to 80% susceptibility = GOOD CHOICE								Less than 80% susceptibility = POOR CHOICE									
Northern Health Authority Gram Positive Organisms % Susceptible	# of Isolates	Amoxicillin	Ampicillin	Cloxacillin	Penicillin	Cefazolin ^A	Cefotaxime or Ceftriaxone	Erythromycin	Clindamycin	Ciprofloxacin	Moxifloxacin	Gent Synergy	TMP-SMX	Tetracycline	Nitrofurantoin ^U	Vancomycin	Linezolid
<i>Staphylococcus aureus</i> †	2398	–	–	76	–	76	–	74	86	–	–	–	92	96	–	100	–
<i>S. aureus</i> (MRSA) ‡	571	R	R	R	R	R	R	R	88	–	–	–	89	92	–	100	100
<i>Staphylococcus epidermidis</i>	303	–	–	53	–	54	–	47	75	–	–	–	77	89	–	100	–
<i>Staphylococcus lugdunensis</i>	138	–	–	94	–	94	–	95	95	–	–	–	99	99	–	100	100
<i>Enterococcus faecalis</i>	518	99 ^B	99	R	–	–	R	R	R	84	–	85	–	–	99	100	–
<i>Enterococcus faecium</i>	95	R	R	R	–	–	R	R	R	12	–	88	–	–	–	50‡	93
Group A <i>Streptococcus</i>	775	100 ^C	100 ^C	–	100	–	100	75	77	–	–	–	R	–	–	99	–
Group B <i>Streptococcus</i>	265	100 ^C	100 ^C	–	100	–	100 ^S	62	59	–	–	–	R	–	–	100	–
Group C <i>Streptococcus</i>	111	100 ^C	100 ^C	–	100	–	100 ^S	76	74	–	–	–	R	–	–	100	–
Group G <i>Streptococcus</i>	167	100 ^C	100 ^C	–	100	–	100 ^S	77	75	–	–	–	R	–	–	100	–
<i>Streptococcus pneumoniae</i>	76	87	–	–	100 ²	–	100 ²	64	–	–	100	–	66	–	–	100	–
					72 ³		87 ³										

Notes Percent susceptible for each organism/antimicrobial combination was generated by including the first isolate of that organism encountered on a given patient.
Organisms with less than 30 isolates have decreased statistical validity.

Legend

- Drug not tested or indicated
- ^S AST method not validated for this organism/antibiotic combination
- † Total *Staphylococcus aureus* isolates (includes MSSA and MRSA)
- ‡ Represents clinical isolates – excludes colonization
- ^U Urinary tract infections only
- R** Intrinsic resistance
- ² Non-meningitis
- ³ Meningitis
- ^A Extrapolated from Cloxacillin
- ^B Extrapolated from Ampicillin
- ^C Extrapolated from Penicillin

* Prepared by Ally King, Regional Program Lead, Microbiology, based on 2024 NHA cumulative AST data from Jan. 1 2024 to Dec. 31 2024,
As per CLSI document M39-A4 Analysis and presentation of cumulative antimicrobial susceptibility tests data – approved guideline – 4th edition

Northern Health Authority Annual Antibigram 2025*

Greater than or equal to 80% susceptibility = GOOD CHOICE								Less than 80% susceptibility = POOR CHOICE									
Northern Health Authority Gram Positive Organisms % Susceptible	# of Isolates	Amoxicillin	Ampicillin	Cloxacillin	Penicillin	Cefazolin ^A	Cefotaxime or Ceftriaxone	Erythromycin	Clindamycin	Ciprofloxacin	Moxifloxacin	Gent Synergy	TMP-SMX	Tetracycline	Nitrofurantoin ^U	Vancomycin	Linezolid
<i>Staphylococcus aureus</i> †	2398	–	–	76	–	76	–	74	86	–	–	–	92	96	–	100	–
<i>S. aureus</i> (MRSA) ‡	571	R	R	R	R	R	R	R	88	–	–	–	89	92	–	100	100
<i>Staphylococcus epidermidis</i>	303	–	–	53	–	54	–	47	75	–	–	–	77	89	–	100	–
<i>Staphylococcus lugdunensis</i>	138	–	–	94	–	94	–	95	95	–	–	–	99	99	–	100	100
<i>Enterococcus faecalis</i>	518	99 ^B	99	R	–	–	R	R	R	84	–	85	–	–	99	100	–
<i>Enterococcus faecium</i>	95	R	R	R	–	–	R	R	R	12	–	88	–	–	–	50‡	93
Group A <i>Streptococcus</i>	775	100 ^C	100 ^C	–	100	–	100	75	77	–	–	–	R	–	–	99	–
Group B <i>Streptococcus</i>	265	100 ^C	100 ^C	–	100	–	100 ^S	62	59	–	–	–	R	–	–	100	–
Group C <i>Streptococcus</i>	111	100 ^C	100 ^C	–	100	–	100 ^S	76	74	–	–	–	R	–	–	100	–
Group G <i>Streptococcus</i>	167	100 ^C	100 ^C	–	100	–	100 ^S	77	75	–	–	–	R	–	–	100	–
<i>Streptococcus pneumoniae</i>	76	87	–	–	100 ²	–	100 ²	64	–	–	100	–	66	–	–	100	–
					72 ³		87 ³										

Notes Percent susceptible for each organism/antimicrobial combination was generated by including the first isolate of that organism encountered on a given patient.
Organisms with less than 30 isolates have decreased statistical validity.

Legend

- Drug not tested or indicated
- ^S AST method not validated for this organism/antibiotic combination
- † Total *Staphylococcus aureus* isolates (includes MSSA and MRSA)
- ‡ Represents clinical isolates – excludes colonization
- ^U Urinary tract infections only
- R** Intrinsic resistance
- ² Non-meningitis
- ³ Meningitis
- ^A Extrapolated from Cloxacillin
- ^B Extrapolated from Ampicillin
- ^C Extrapolated from Penicillin

* Prepared by Ally King, Regional Program Lead, Microbiology, based on 2024 NHA cumulative AST data from Jan. 1 2024 to Dec. 31 2024,
As per CLSI document M39-A4 Analysis and presentation of cumulative antimicrobial susceptibility tests data – approved guideline – 4th edition